cyrilzakka/clinical-trials huggingface dataset:
Analysis of Motor Skills in Subjects Aged 55 and Over: the Role of Cognitive Abilities for Planning Movement.

Falling is an event that is more frequent and severe in older age. It can lead to a loss of autonomy and a decrease in quality of life. It is therefore important to understand this phenomenon in order to better prevent it. Among the multiple risk factors associated with falling, recent research has shown a link between the decline in cognitive abilities (i.e., the mental processes that form our knowledge, such as memory) and the risk of falling. However, the impact of this cognitive decline on motor skills is still poorly understood. The purpose of this research is to study how the changes induced by aging affect motor skills. This would make it possible to take a new look at the phenomenon of falls occurring in the elderly and, in the long term, to improve the prevention and rehabilitation.


Eligibility Criteria:
Inclusion Criteria:

1. Neurotypical subjects group:

   * Person aged 18 to 40 years
   * Person who has given oral consent
   * Affiliated to national health insurance
   * Right-handed person
2. Group of elderly neurotypical subjects:

   * Person over 55 years of age
   * Person who has given oral consent
   * Affiliated to national health insurance
   * No cognitive problems (MMSE score \>26)
   * Right-handed person
3. Elderly mild cognitive disorder subject group:

   * Person over 55 years of age
   * Person who has given oral consent
   * Diagnosis of Mild Cognitive Disorder made by a neurologist at the Centre Mémoire Ressources et Recherche (CMRR) of the University Hospital of Dijon, following the recommendations of the National Institute for Aging and Alzheimer's Association (Albert et al., 2011) This diagnosis is based on psychometric tests, brain imaging and the evolution of cognitive disorders, including an MMSE test.
   * Right-handed person

Exclusion Criteria:

* Neurological or psychiatric history with the exception of the TCL group.
* Follow-up of drug treatment in the last three months that may affect cognitive and/or motor skills.
* Received a shoulder prosthesis on the dominant side.
* Received a hip and/or knee replacement less than a year ago.
* Disabling joint disease of the hip or knee shoulder
* Protected adults (curatorship, guardianship)
* Person deprived of their liberty b judicial or administrative decision
* Pregnant, parturient or breastfeeding woman
* Major unable to consent
Evaluation of EEG With Respect to the Change of Depth of Anesthesia During General Anesthesia

The BIS Index, one of the VISTA Monitor output parameters, may be used as an aid in monitoring the effects of certain anesthetic agents;and its usage with certain anesthetic agents may be associated with a reduction in primary anesthetic use and a reduction in emergence and recovery time.

However, this equipment does not give the proper anesthetic depth index is a number of experimental results have been reported.

Therefore, the investigators study that the BIS VISTA receives an electroencephalogram (EEG) obtained through the depth of anesthesia monitors brain waves to collect statistical data, through mathematical analysis to analyze the exact correlation between the patient's brain waves and the depth of anesthesia.

General anesthesia is accompanied during surgery gives a lot of satisfaction and impact on surgical outcomes of patients depending on the dose of the anesthetic, as well as operation time and intensity.

The BIS Index, one of the VISTA Monitor output parameters, may be used as an aid in monitoring the effects of certain anesthetic agents;and its usage with certain anesthetic agents may be associated with a reduction in primary anesthetic use and a reduction in emergence and recovery time.

However, this equipment does not give the proper anesthetic depth index is a number of experimental results have been reported.

Therefore, the investigators study that the BIS VISTA receives an electroencephalogram (EEG) obtained through the depth of anesthesia monitors brain waves to collect statistical data, through mathematical analysis to analyze the exact correlation between the patient's brain waves and the depth of anesthesia.

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologist\[ASA\] class 1-2
* written informed consent

Exclusion Criteria:

* allergy of neuromuscular blocking drugs or other medications used during general anesthesia
* known or suspected upper respiratory infection
* suspected difficult tracheal intubation
* Uncontrolled Hypertension
* known or suspected psychologic disorder
* known or suspected significant renal dysfunction
* known or suspected severe hepatic dysfunction
* known or suspected significant cardiovascular dysfunction
Comparison of Two Behavioral Treatments for Stress Reduction

Currently there are 2 popular stress reduction courses that are widely used in the US. Although they use somewhat similar techniques, it is currently unknown whether or not they work the same way, or if they are similarly effective at reducing stress. The study will directly compare these 2 courses. Participants will undergo approximately 4-5 hours of testing before and after each 8-week course.


Eligibility Criteria:
Inclusion Criteria:

* 25 to 60 years old
* Good general health
* Able to attend all 8 sessions of the course and practice the techniques each night for 25 minutes

Exclusion Criteria:

* Psychiatric medications
* Significant medical or psychological illness
* Metalic implants (such as a pacemaker or artificial joints) that are not MRI compatible.
* Claustrophobia
* Pregnancy
* Previous head trauma or neurological disorder
* Previous experience with yoga or meditation
Sleeper Stretch in CrossFit Participants

The purpose of this study is to compare the efficacy of the sleeper stretch in improving shoulder range of motion, strength and upper body performance in CrossFit athletes.


Eligibility Criteria:
Inclusion Criteria:

• Regularly active (attending CrossFit \> 2x per week)

Exclusion Criteria:

* Positive test for labral lesions or rotator cuff tears
* History of recent fracture
* Orthopedic surgery in the upper limbs or cervical region
* Any other current injury that would prevent participation in regular work-shift activities
Detection of Renal Malignancy of Complicated Renal Cysts

The aim of this study was to show additional diagnostic criteria of computed tomography (CT) scan to diagnose and predict the detection and recurrence of cystic renal cell carcinoma in the patients with complicated renal cysts. Furthermore, we would demonstrate the relationship between complicated renal cysts diagnosed by Bosniak system and some parameters of pathological results. The analysis about detection time of renal malignancy would help determine the practical guidelines of follow-up plan for complicated renal cysts.

Even though there have been many trials and errors to enhance the diagnostic accuracy of CT scans for complicated cysts, the trial to obtain the enhanced accuracy using CT scan would be still valuable, when we consider its widespread use. A previous study demonstrated that the enhancement of HU with intravenous administration of contrast material on CT scan by 15 HU would be "almost always indicative of a pathologic process although not always a malignancy", another study showed the cut-off as 42 or 47 HU gap would be helpful in the prediction of renal malignancy.

Eligibility Criteria:
Inclusion Criteria:

* All patients who were diagnosed as renal cysts
* available serial follow-up data of CT scan
* all CT imaging included non-enhanced (NEP), corticomedullary (CMP), and early excretory phase (EEP) scans. The scan delay times should range from 30 to 40 seconds for CMP scans and from 120 to 180 seconds for EEP scans.

Exclusion Criteria:

* cases diagnosed by only US/MR
* no serial CT images
* cysts of autosomal dominant adult polycystic kidney disease
* cysts less than 1cm in diameter (difficult to evaluate accurately)
* follow-up period less than 1 yr in the patients who had no surgery
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis

The purpose of this exploratory sub-study was to evaluate from a clinical perspective the impact on disease activity of lowering the dose of abatacept from 10 mg/kg to 5 mg/kg in subjects who had achieved remission (Disease Activity Score 28 \[DAS 28\]-erythrocyte sedimentation rate \[ESR\] \< 2.6) at Day 701 of study IM101023.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who have completed the main study, are willing to participate and have a DAS 28 ESR score of \< 2.6 on Day 701 of the main study

Exclusion Criteria:

* None
Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Pemetrexed was known to be effective to pulmonary adenocarcinoma and gefitinib was known to be more effective to non-small cell lung cancer (NSCLC) patients with clinical characteristics such as adenocarcinoma, never smoker and female.

The investigators try to evaluate which drug (pemetrexed vs gefitinib) is more efficious to NSCLC patients with clinical characteristics such as adenocarcinoma and never smoking history as second- or further-line therapy.


Eligibility Criteria:
Inclusion Criteria:

1. Histologically confirmed pulmonary adenocarcinoma including bronchioloalveolar, but except adenosquamous cell carcinoma
2. Stage IIIB (malignant pleural effusion and/or pleural seeding), stage IV and relapsed non-small cell lung cancer
3. Failed with 1st line platinum-based chemotherapy or relapsed within 12 months after adjuvant platinum-based chemotherapy)
4. Never smoker (less than 100 cigarette for the life time)
5. 18 year or older
6. ECOG 0-2
7. No history of biologic or immunotherapy
8. Tolerable renal function ( creatine clearance rate is 60ml/min or more)
9. Tolerable hepatic function (Serum bilirubin ≤ 1.25 x UNL, AST (SGOT) and ALT (SGPT) ≤ 2.5 x UNL, alkaline phosphatase ≤5 x UNL)

Exclusion Criteria:

1. symptomatic brain metastasis
2. previously treated with EGFR tyrosine kinase inhibitor
3. previously treated with antifolate agents
4. poor oral absorption
5. patients with active infection
6. uncontrolled diabetes mellitus
7. significant cardiovascular disease (uncontrolled hypertension, history of myocardial infarction or unstable angina within 6 months, congestive heart failure)
8. pregnant or nursing patients
9. history of malignant disease within 3 years before the enrollment except for cured non-melanomatous skin cancer, cervical carcinoma in situ, or thyroid carcinoma
Oral Colecalciferol Treatment in Spinal Cord Lesion

Low vitamin D is frequently seen in patients with spinal cord injury (SCI) in acute and chronic periods. Among its causes are insufficient sun exposure, limited oral intake, obesity, the effect of the drugs used on the absorption of vitamin D, kidney and liver diseases. If we consider patients with spinal cord injuries in Turkey, it is difficult to get involved in the society, low exposure to the sun, lack of necessary health controls and immobility brings extra risk factors for the low vitamin D compared to the general population. Despite Turkey Endocrinology and Metabolism Endocrine Society and the International Endocrine Association clinical practice guidelines do not provide specific recommendations about vitamin D, for individuals with spinal cord injuries. Individuals with SCI are at high risk for low vitamin D. Vitamin D levels need to be checked and replaced. Vitamin D doses, application methods and dose intervals used in Physical Therapy and Rehabilitation clinics are different. The aim of our study is to perform the necessary vitamin D replacement for individuals with SCI who have vitamin D deficiency in different dose intervals and to compare the effects of muscle strength, muscle thickness and functional independence with the control group.

Paraplegic patients who admitt to our Physical Therapy and Rehabilitation Clinic, will be included in the rehabilitation program. Sixty spinal cord injured patients with serum 25 (OH) D3 levels less than 20 ng / ml will be included in the study. One of the treatment groups will receive 6,000 IU of vitamin D daily, and the other group 50,000 IU of vitamin D per week for eight weeks. Patients with high calcium (Ca) values in blood tests, patients with kidney stones and urinary stones in urinary ultrasonography (USG) to be performed routinely, as well as patients who refuse to use vitamin D supplements will include in the control group. Spinal cord independence measure (SCIM version 3) will be filled in at the beginning and at the end of 8 weeks to all participants. Jamar Dynamometer will be measured for upper extremity muscle strength, and biceps brachii and triceps muscle thicknesses will be measured by ultrasonography.

Eligibility Criteria:
Inclusion Criteria:

1. 18-60 years old
2. Thoracic level chronic spinal cord injury
3. A, B, C, D complete / incomplete patients according to ASIA classification
4. 25 (OH) D3 level in serum is \<20 ng / ml
5. Complete muscle strength in upper extremity

Exclusion Criteria:

1. Individuals with chronic liver, kidney, respiratory and parathyroid disease
2. Chronic constipation
3. Patients who have recently used vitamin D
4. Use of drugs that will affect vitamin D and Ca level (Thiazide group diuretics, statins)
5. Acute inflammation (may show false low in vitamin D levels)
Evaluation of Functional Status and Mental Functions of Adult Cerebral Palsy Patients

In adult cerebral palsy patients , a questionnaire study will be conducted to determine the functional level and to determine the effect on quality of life. In this survey, age, gender, demographic information of the patient, as well as additional diseases which can be seen together with cerebral palsy will be questioned.

In adult patients diagnosed with cerebral palsy, a questionnaire study will be conducted to determine the functional level and to determine the effect on quality of life. In this survey, age, gender, demographic information of the patient, as well as additional diseases which can be seen together with cerebral palsy will be questioned. There are studies about the functional status of adults with CP in the literature; However, there is no study conducted on this subject in our country. In this study, it was aimed to evaluate the functional status and mental functions of adults with CP who applied to our hospital.

Eligibility Criteria:
Inclusion Criteria:

* \>18 years old
* Diagnosed with cerebral palsy
* Who voluntarily participate the study

Exclusion Criteria:

* \<18 years old
* Who does not give permission to participate the study
A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs

The goal of this study is to determine the association between genotypes and diet. The weight and weight loss data are already available from the previously completed study called: A to Z Study - Benefits and Risks of Alternative Weight Loss Strategies - A Clinical Trial, which was performed from 2003-2005 at Stanford University. In the present study, Interleukin Genetics will obtain DNA samples from the previously enrolled study subjects to investigate genetic influence of the response to macronutrient compositions of low caloric diets to weight loss.

Interleukin Genetics has derived, through an extensive search of the scientific literature, a genetic test panel in the area of Weight Management (WM), which includes the genes that have been shown to affect body weight. These genes have been associated with elevated risk for obesity.

Eligibility Criteria:
Inclusion Criteria:

* BMI (body mass index): 27-40 kg/m2
* Gender: Women only
* Age: 25-50
* Menopausal status: pre-menopausal
* Weight stable for last 2-months
* Not on a weight loss plan
* No ethnic restrictions
* No plans to move from the area over the next 6-months
* Willing to accept random assignment
* Possess English speaking and reading skills to understand and complete forms such as informed consent and study evaluation

Exclusion Criteria:

* Hypertension
* Diabetes (type 1 or 2) or history of gestational diabetes
* Heart disease diagnosis
* Renal or lever disease
* Active neoplasms
* Pregnant, lactating, within 6-months of birth, or planning to become pregnant in the next 6-months
* Hyperthyroidism, unless treated and under control
* Medications known to affect weight / energy expenditure
* Excessive alcohol intake (self-reported, \> 3 drinks/day)
* Postmenopausal, including surgical menopause
* Currently under psychiatric care, or severely clinically depressed (\>17 on Beck Inventory)
Feasibility Assessment of ACS Catheter

This is a single centre, non-randomised, baseline controlled, prospective pilot clinical trial to be undertaken at Rotherham General Hospital, Rotherham, UK.

The study will examine the safety and performance of a new urinary catheter, the Alternative Catheter System (ACS) (Alternative Urological Catheter Systems Ltd (AUCS), Bristol, UK) which has been developed to reduce the morbidity of long-term catheterisation and the acknowledged deficiencies of the conventional Foley urinary catheter.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female, at least 18 years of age.
2. Patient or authorised representative must be able to comprehend and sign the Informed Consent Form prior to enrolment in the study.
3. Capable of using a catheter valve to empty the bladder and able to communicate their experience with the system OR who has a carer able to fulfil these tasks.
4. Fitted with a suprapubic catheter (at least 2 weeks post insertion).
5. Ability to attend out-patient clinic at regular intervals throughout the study and able to participate for a maximum of 8 weeks.
6. History of catheter blockages, bypassing or episodes of pyrexia and bacteraemia in the last 2 months.

Exclusion Criteria:

1. \<18 years of age.
2. Pregnant or lactating females.
3. History of catheter associated septicaemia in the past month.
4. Evidence of current systemic infection.
5. Bladder pathology such as a tumour or stone \>0.5cm as determined by cystoscopy.
6. Flaccid bladder.
7. BMI\>35.
8. Current participation in another device or drug study.
9. Unwilling or unable to provide informed consent.
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to 10 mg of Vortixetine and placebo in participants with major depressive disorder (MDD).


Eligibility Criteria:
Inclusion Criteria:

* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD
* Current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1
* Have inadequate response to 1-3 antidepressant therapies given at adequate dose and duration in the current episode
* If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test

Exclusion Criteria:

* DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
* Lifetime history of meeting DSM-5 criteria for:

  1. Schizophrenia spectrum or other psychotic disorder
  2. Bipolar or related disorder
  3. Major neurocognitive disorder
  4. Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
  5. Dissociative disorder
  6. Posttraumatic stress disorder
  7. MDD with psychotic features
* Significant suicide risk, as judged by the Investigator
Repetitive Transcranial Magnetic Stimulation With Double Cone Coil in Chronic Tinnitus

Transcranial Magnetic Stimulation is used to modulate both the auditory neural pathways contributing to the perception of phantom sounds, and the regulatory neural network responsible for the generation of the individual amount of suffering caused by chronic tinnitus.

Tinnitus is the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus. It is a frequent problem which can interfere significantly with the ability to lead a normal life. Treatment remains difficult. Most available therapies focus on habituation rather than treating the cause. Tinnitus has been shown to be generated in the brain, as a result of functional reorganization of auditory neural pathways and tonotopic maps in the central auditory system. Low-frequency rTMS applied to the temporoparietal areas has been investigated for the treatment of hyperexcitability disorders such as auditory hallucinations and tinnitus. Pilot data indicate that taking into account affective components of the multiple overlapping neural networks responsible for the generation of a bothersome subjective tinnitus might enhance the efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) treatment in chronic tinnitus. A newly developed coil, the so-called double cone coil will be examined with regard to feasibility, safety and clinical efficacy in patients suffering from chronic tinnitus in a controlled pilot trial.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of bothersome, subjective chronic tinnitus
* Duration of tinnitus more than 6 months

Exclusion Criteria:

* Objective tinnitus
* Treatable cause of the tinnitus
* Involvement in other treatments for tinnitus at the same time
* Clinically relevant psychiatric comorbidity
* Clinically relevant unstable internal or neurological comorbidity
* History of or evidence of significant brain malformation or neoplasm, head injury
* Cerebral vascular events
* Neurodegenerative disorder affecting the brain or prior brain surgery;
* Metal objects in and around body that can not be removed
* Pregnancy
* Alcohol or drug abuse
* Prior treatment with TMS